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The effect of breast cancer surgery timing during the menstrual cycle on prognosis remains controversial. We conducted a
multicentre prospective study to establish whether timing of interventions influences prognosis. We report 3-year overall and
disease-free survival (OS/DFS) results for ‘primary analysis’ patients (regular cycles, no oral contraceptives within previous 6 months).
Data were collected regarding timing of interventions in relation to patients’ last menstrual period (LMP) and first menstrual period
after surgery (FMP). Hormone profiles were also measured. Cox’s proportional hazards model incorporated LMP in continuous form.
Exploratory analyses used menstrual cycle categorisations of Senie, Badwe and Hrushesky. Hormone profiles with LMP and FMP data
were also used to define menstrual cycle phase. Four hundred and twelve ‘primary analysis’ patients were recruited. Three-year OS
from first surgery was 90.7, 95% confidence interval (CI) [87.9, 93.6%]. Menstrual cycle according to LMP was not statistically
significant (OS: hazard ratio (HR)¼1.02, 95%CI [0.995,1.042], P¼0.14; DFS: HR¼1.00, 95%CI [0.980,1.022], P¼0.92). Timing of
surgery in relation to menstrual cycle phase had no significant impact on 3-year survival. This may be due to 97% of patients receiving
some form of adjuvant therapy. Survival curves to 10 years indicate results may remain true for longer-term survival.
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Interest in the influence of the menstrual cycle phase at the time of
surgery, especially in patients with primary breast cancer, has been
the subject of much controversy over the last 20 years. In 1988
Ratajczak et al (1988), using a mouse model, showed a relationship
between the incidence of postoperative pulmonary metastasis and
timing of mammary tumour removal within the reproductive
cycle. The following year Hrushesky and co-workers performed a
retrospective review of 44 premenopausal women and showed that
survival varied according to timing of surgery in the menstrual
cycle. They concluded that patients operated on during the
perimenstrual period of the cycle had worse disease-free (DFS)
and overall survival (OS) than patients who were operated on
during other phases of the cycle. Further studies found differing
results; some (Badwe et al, 1991; Veronesi et al, 1994) supported
the hypothesis (albeit with different days of heightened risk),
others found no effect (Goldhirsch et al, 1991; Nathan et al, 1993)
and one (Sainsbury et al, 1991) found an opposite effect, with
patients operated on in the follicular phase surviving longer than
those operated on in the luteal phase.
All the above studies were retrospective and relied on the
patients’ recall of their last menstrual period (LMP) before surgery.
This was not available for all patients and its accuracy was not
known. It also assumed that ovulation took place 15 days after the
first day of menstruation. The subject was reviewed by McGuire
(1991) who was critical of the methodology. He demonstrated that
changing the definition of duration of the phase of the natural
cycle by a couple of days shifted significant numbers of patients
from a luteal to a follicular (or vice versa) phase.
In 1992 we instituted the Yorkshire Breast Cancer Group
Intervention, Timing and Survival (ITS) study, a multicentre,
prospective, observational study of premenopausal women pre-
senting with de novo breast cancer, aiming to investigate whether
the prognosis for breast cancer patients varies according to the
phase of the menstrual cycle during which surgery is performed.
Here we report the results of 3-year overall and DFS for the
‘primary analysis’ group. This consisted of those patients who had
regular menstrual cycles (i.e. whose duration of menstrual cycle
varied by less than 5 days each month) and had not taken the oral
contraceptive pill within the previous 6 months before study
recruitment in order that hormonal profiles of patients remained
as homogeneous as possible.
MATERIALS AND METHODS
Premenopausal women with suspected operable primary breast
cancer were eligible for study entry. Exclusion criteria were
previous cancer (except non-melanoma skin cancer or in situ
cancer of the cervix), pregnancy at the time of diagnosis, having
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staken hormone replacement therapy within 6 months before
diagnosis, screen-detected cases or patients who had had a
hysterectomy. Patients were not randomised to undergo interven-
tions at a specified phase of their menstrual cycle and current
treatment practice was maintained within each participating
centre. Since ITS was a non-randomised observational study,
patients identified as ineligible, for example, due to non-malignant
tumours, were not followed up. The ITS study received approval
from multicentre and local research ethics committees.
Data were collected regarding the timing of interventions (first
tumour handling (FTH) and subsequent surgeries) in relation to
patients’ menstrual cycle. The date of the LMP before each
intervention, hormonal profiles (progesterone, oestradiol, follicle-
stimulating hormone and luteinising hormone) at each interven-
tion and the date of the first menstrual period after first surgery
(LMP) were collected. Data were also collected regarding adjuvant
treatment (chemotherapy, endocrine therapy and/or radiotherapy)
administration and site of postoperative radiotherapy, and
pathology.
The primary 3-year endpoint was OS, with DFS, local
recurrence-free survival and systemic recurrence-free survival at
3 years as secondary endpoints. The key 3-year primary endpoint
was OS from first surgery. Longer-term survival will be reported at
10 years.
Due to the uncertainty of the influence of the timing of
interventions in relation to the menstrual cycle phase on
prognosis, and of the most appropriate categorisation of the
menstrual cycle into phases, the primary aim of the ITS study was
to identify whether the timing of interventions does indeed affect
outcome, and to investigate an optimal interval for surgery. Using
only the date of the LMP, patients were therefore categorised into
one of seven menstrual cycle groups (0–4, 5–9, 10–14, 15–19,
20–24, 25–29 and 30þ days between LMP and intervention) for
the initial analysis. Last menstrual period was also categorised
according to the menstrual cycle phase definitions of Senie et al
(1991) (luteal: days 15–36; follicular: days 0–14), Badwe et al
(1991) (luteal: days 0–2 and 13–32; follicular: days 3–12) and
Hrushesky et al (1989) (mid-cycle: days 7–20; perimenstrual: days
0–6 and 21–32). Patients were also categorised as being in either
the luteal or follicular phase of their menstrual cycle at the time of
intervention using LMP, FMP and hormonal profiles at the time of
intervention, along with data regarding menstrual cycle length and
variation, in order that patients’ phase of menstrual cycle at the
time of intervention could be identified as accurately as possible.
This categorisation was performed by an independent expert who
was blinded to patients’ outcome.
Since the primary aim of this study was to consider whether the
timing of surgery affects prognosis, that is, not a specific
comparison of groups, the sample size calculation was based on
the number of patients required to investigate the optimal interval
of the menstrual cycle. To ensure that each of the above seven
menstrual cycle groups had an adequate number of patients (60–65
patients per group) and an adequate number of events for the
analysis of the optimal interval (Harrell et al, 1985), between 400
and 450 patients were therefore needed to be recruited to the
‘primary analysis’ group. In the event that two phases of the
menstrual cycle would be identified as important with regard to
the timing of surgery, recruitment of between 300 and 450 patients
would be sufficient to detect a clinically relevant difference of at
least 10%, with 85% power, for various underlying survival
patterns.
Overall survival was defined as time from intervention to death
from all causes, and DFS was defined as time from intervention to
recurrence or death from all causes. Follow-up beyond 3 years of
intervention was censored. Kaplan–Meier curves were calculated
to compare OS and DFS by menstrual cycle phase defined using
the various categorisations (as described above), and differences in
survival between the seven LMP groups of menstrual cycle were
tested using the log-rank and Wilcoxon tests. Cox’s proportional
hazards (PH) model was used to assess the independent influence
of timing of intervention in relation to the phase of menstrual cycle
on survival, adjusting for Nottingham Prognostic Index (NPI),
type of intervention and adjuvant therapies (chemotherapy,
radiotherapy and hormone therapy). Analysis incorporated LMP
into the Cox model in its continuous form (Altman and Lyman,
1998), and subsequent exploratory analyses considered the
categorisations of Senie and co-workers, Badwe and co-workers
and Hrushesky and co-workers, and menstrual cycle phases
defined using hormone profiles with LMP and FMP data. In order
to identify a possible optimal interval of timing of surgery in
relation to the phase of menstrual cycle according to LMP, the
statistical methods employed by Keefe and Mackie (1991) were
used on the key 3-year primary endpoint. The deviance for the Cox
PH model where phase of menstrual cycle was considered as a
factor variable, using the seven categorisations of LMP, was
calculated. The mean value within each of these seven groups was
then calculated and substituted for the ordinal factor level in the
Cox PH model (i.e. entered into the model as a regressor variable).
The difference in deviances of the two models was compared with a
w
2-distribution with five degrees of freedom. By comparing these
models we were able to address whether the relationship between
menstrual cycle phase at surgery and survival was linear, or
whether patients could in fact be categorised into groups with
differing probabilities of survival. If an optimal interval were
identified for OS, this optimal categorisation would also be
investigated in the analysis of DFS.
A two-sided 5% significance level was used for the key primary
endpoint of OS from first surgery, and a two-sided 1% significance
level was used for all other endpoints (ICH E9 Expert Working
Group, 1999). No statistical testing was carried out on any
exploratory analyses. All statistical analyses were performed using
SAS Version 8.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Six hundred and eleven patients were recruited to the ITS study
between February 1993 and December 2000, across 24 UK centres
and one Italian centre, and 412 (67.4%) of these patients were in
the ‘primary analysis’ group. Table 1 displays baseline character-
istics for these primary analysis patients. Median follow-up was 59
months (inter-quartile range (IQR)¼[43, 78]) and median age at
first surgery was 43 years (IQR¼[40, 46]). Seventy-four patients
(18.0%) had an excision biopsy as their first surgical intervention,
197 patients (47.8%) had a lumpectomy and 138 patients (33.5%)
had a mastectomy. The median time from FTH to first surgical
intervention was 17 days (IQR¼[10, 26]), and 134 patients
(32.5%) required further surgery. No association was observed
between timing of first surgical intervention in relation to patients’
menstrual cycle phase and the need for further surgery (data not
displayed). Figure 1 shows a breakdown of the primary analysis
group patients for 3-year survival from first surgery.
Overall survival from first surgery at 3 years for all primary
analysis group patients was 90.7% (95% confidence interval (CI)
[87.9, 93.6%]). Table 2 shows the number of deaths and censored
values according to the seven LMP groups, under univariate
analysis. No statistically significant differences in 3-year OS were
identified between the seven LMP groups (log-rank¼1.52, df¼6,
P¼0.96). Under multivariate analysis, 366 patients were included.
Menstrual cycle according to LMP at the time of first surgery and
incorporated into the Cox PH model in its continuous form was
not found to be a statistically significant independent predictor of
3-year OS (likelihood ratio¼2.13, df¼1, P¼0.14) (Table 3).
Nottingham Prognostic Index was found to be the only statistically
significant factor contributing towards OS (likelihood
ratio¼29.77, df¼1, Po0.0001, hazard ratio (HR)¼2.34, 95% CI
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s[1.73, 3.18]) under multivariate analysis. Results for OS from FTH
were similar.
In identifying an optimal interval for LMP, Figure 2 displays
HRs and 95% CIs for each of the seven LMP groups, with the ‘0–4
days’ group being the reference group. The HRs were shown not to
† Last menstrual period (LMP)
‡  Disease-free survival (DFS) 
Primary analysis group
412 patients
Neo-adjuvant treatment  
only 1 patient  Lost to follow-up
1 patient
Overall survival
397 patients
Disease-free survival
392 patients
DFS‡ status unable to be  
identified 5 patients
No LMP  data
13 patients
Figure 1 Flow chart of primary analysis group patients for 3-year survival
analysis from first surgery.
Table 1 Baseline characteristics of the 412 patients in the primary
analysis group
n %
Patients who had mammography 364 88.3
Patients who had fine-needle aspiration 365 88.6
Patients who had a core biopsy 55 13.3
Age at first surgery (years) – median (Q1, Q3) 43 (40, 46)
(min., max.) (22, 54)
LMP group at first surgery
0–4 days 64 15.5
5–9 days 70 17.0
10–14 days 61 14.8
15–19 days 62 15.0
20–24 days 71 17.2
25–29 days 39 9.5
30+ days 31 7.5
Unidentifiable
a 14 3.4
Type of first surgery
Excision biopsy 74 18.0
Lumpectomy 197 47.8
Mastectomy 138 33.5
Axillary procedure only 1 0.2
Neoadjuvant therapy 1 0.2
Missing 1 0.2
Type of axillary procedure at first surgery
None 100 24.3
Sample 69 16.7
Clearance 243 59.0
Further surgery required 134 32.5
Adjuvant treatment received 402 97.6
Chemotherapy given 278 69.2
Hormone therapy given 278 69.2
Radiotherapy given 320 79.6
Histological grade
I 59 14.3
II 181 43.9
III 154 37.4
Missing 18 4.4
Tumour size (mm) – median (Q1, Q3) 20 (15, 30)
(min., max.) (0.5, 150)
Number of nodes sampled – median (Q1, Q3) 11 (7, 16)
(min., max.) (0, 36)
Nodal status
Positive 208 50.5
Negative 193 46.8
Missing 11 2.7
NPI prognostic groups – three categories
Good 110 26.7
Moderate 176 42.7
Poor 95 23.1
Missing 31 7.5
LMP¼last menstrual period; NPI¼Nottingham Prognostic Index.
aPatients whose
LMP date or surgery date is missing, or who had neoadjuvant therapy, are classed as
having an unidentifiable LMP group.
Table 2 Number of deaths and censored values for univariate 3-year OS
from first surgery analysis according to the seven LMP groups
LMP group
Number of
patients Died Alive
a
Lost to
follow-up
b
Overall survival
at 3 years
0–4 days 64 6 56 2 90.3
5–9 days 70 5 62 3 92.6
10–14 days 61 4 53 4 93.3
15–19 days 62 6 53 3 90.1
20–24 days 70 7 60 3 89.7
25–29 days 39 4 33 2 89.5
30+ days 31 4 25 2 86.9
Total 397 36 342 19 90.7
LMP¼last menstrual period; OS¼overall survival.
aPatients censored at 3 years.
bPatients censored before 3 years (at the time they were last known to be alive).
Table 3 Results of multivariate analysis of 3-year OS from first surgery,
menstrual cycle according to LMP incorporated in its continuous form
Estimate
Standard
error
Hazard ratio
[95%
confidence
interval] df
Likelihood
ratio
statistic P-value
Nottingham
Prognostic
Index
0.85 0.16 2.34 [1.73, 3.18] 1 29.77 o0.0001
Hormone
therapy
(yes vs no)
0.65 0.41 1.91 [0.85, 4.30] 1 2.66 0.10
Radiotherapy
(yes vs no)
 0.22 0.47 0.80 [0.32, 2.02] 1 0.21 0.65
Chemotherapy
(yes vs no)
 0.64 0.51 0.53 [0.19, 1.43] 1 1.45 0.23
Type of first
surgery
2 3.12 0.21
Mastectomy
vs excision
biopsy
1.08 0.75 2.93 [0.67, 12.87]
Lumpectomy
vs excision
biopsy
0.63 0.78 1.87 [0.40, 8.68]
Day of
menstrual cycle
0.02 0.01 1.02 [0.995, 1.042] 1 2.13 0.14
LMP¼last menstrual period; OS¼overall survival.
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sbe linear, with the hazards in the ‘5–9 days’, ‘10–14 days’ and
‘20–24 days’ groups being lower in comparison with the ‘0–4 days’
group, while the hazards in the ‘15–19 days’ and ‘25–29 days’
groups were higher. Confidence intervals were however wide and
all contained the value one. According to the method of Keefe and
Mackie (1991), it was found that there was no significant benefit of
fitting LMP as a factored variable compared with a regressor
variable (likelihood ratio¼2.77, df¼5, P¼0.74), indicating that
there may not be a step function relationship between survival
and LMP according to the seven-group categorisation. Hence no
optimal interval for LMP was identified.
Where menstrual cycle was categorised into the follicular or
luteal phase according to hormonal profiles with LMP and FMP
data, of the 412 patients in the primary analysis group, one patient
received neoadjuvant therapy only, 82 patients did not have
available hormonal data at first surgery and a further 73 patients
could not be accurately identified as being in either the luteal or
follicular phase of their menstrual cycle. Two hundred and fifty-six
patients (62.1%) were therefore included in analysis. Figure 3
displays 3-year OS from first surgery for the two menstrual cycle
phases considered here. No differences in survival were seen.
Under multivariate analyses, menstrual cycle phase as defined
above was not found to be an independent predictor of 3-year OS
(HR¼0.67, 95% CI [0.28, 1.63]). When phase of menstrual cycle
was categorised according to Senie and co-workers, Badwe and
co-workers and Hrushesky and co-workers using LMP, results
were similar and no effect of timing of surgery in relation to phase
of menstrual cycle was found (results not displayed).
Three-year DFS from first surgery for primary analysis group
patients was 83.4% (95% CI [79.7, 87.0%]). Of the 66 patients who
had a recurrence within 3 years of first surgery, 13 patients had a
local recurrence, 51 patients had a systemic recurrence as their
first recurrence and two patients had both a local and systemic
recurrence on the same day. No statistically significant differences
in DFS were found between the seven LMP groups (log-
rank¼0.85, df¼6, P¼0.97). Three hundred and sixty-two
patients were included in multivariate analysis, and since no
optimal interval of the menstrual cycle was identified in the
analysis of OS from first surgery, menstrual cycle defined using
LMP was entered into the Cox’s PH model as a continuous
variable. Menstrual cycle at the time of first surgery was not found
to be a statistically significant independent predictor of 3-year
DFS (likelihood ratio¼0.01, df¼1, P¼0.92) (Table 4). At the 1%
significance level, NPI was found to be the only statistically
significant factor independently contributing towards DFS (like-
lihood ratio¼40.84, df¼1, Po0.0001, HR¼2.21, 95% CI [1.74,
2.81]). Results of DFS from FTH were again similar.
DISCUSSION
In this study, timing of surgery within the menstrual cycle had no
significant impact on 3-year survival. Our patients were carefully
stratified on the basis of regularity of cycles, and in this analysis,
only patients who had regular menstrual cycles and who had not
taken the oral contraceptive pill within the previous 6 months were
included. Menstrual cycle phase was also assessed both by LMP
data as well as hormonal data. In addition, the question of whether
it is FTH (mammography, cytology or core biopsy) or surgical
intervention that is important can be addressed, as menstrual cycle
data were collected for each intervention (including further
surgery), making this study unique. However, results for survival
from FTH were similar to those from first surgery, which may be
expected since median time from FTH to first surgical intervention
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Figure 3 Three-year OS from first surgery according to menstrual cycle
phase defined using hormone profiles with LMP and FMP data.
Table 4 Results of multivariate analysis of 3-year DFS from first surgery,
menstrual cycle according to LMP incorporated in its continuous form
Estimate
Standard
error
Hazard ratio
[95%
confidence
interval] df
Likelihood
ratio
statistic P-value
Nottingham
Prognostic Index
0.79 0.12 2.21 [1.74, 2.81] 1 40.84 o0.0001
Hormone therapy
(yes vs no)
0.17 0.29 1.19 [0.67, 2.10] 1 0.35 0.55
Radiotherapy
(yes vs no)
0.09 0.38 1.09 [0.52, 2.29] 1 0.06 0.81
Chemotherapy
(yes vs no)
 0.86 0.37 0.42 [0.21, 0.88] 1 4.87 0.03
Type of first
surgery
2 0.30 0.86
Mastectomy
vs excision
biopsy
0.01 0.44 1.01 [0.43, 2.38]
Lumpectomy
vs excision
biopsy
 0.15 0.44 0.86 [0.36, 2.04]
Day of menstrual
cycle
0.001 0.01 1.00 [0.98, 1.02] 1 0.01 0.92
DFS¼disease-free survival; LMP¼last menstrual period.
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swas only 17 days. In 2002, Hortobagyi (2002) reviewed the subject
of menstrual cycle phase influence on timing of surgical treatment
for breast cancer and concluded that the only reliable method to
confirm the hypothesis suggested by Hrushesky et al (1989) was a
prospective trial in which participants have careful hormone
measurements performed at each intervention to determine their
menopausal status and the menstrual cycle phase.
Although there were low numbers of deaths in comparison with
the NPI expected event rate within 3 years, this study was
adequately powered, and a sufficient number of events were
observed, to detect an effect as large as that seen by Badwe et al
(1991). Figure 4 shows OS to 10 years for primary analysis group
patients where phase of menstrual cycle is categorised according to
the definition of Badwe and co-workers using LMP. This figure
shows that the results of no impact of the timing of surgery with
respect to the menstrual cycle phase may remain true for longer-
term survival; however, it is important to note that not all patients
have been followed up for 10 years, and so longer-term follow-up
is still required to confirm this.
This study also has the advantage that no change in routine
practice was required, or was seen, thus avoiding a potential bias
and ethical dilemma of allocating patients to have surgery within
one particular phase of the cycle, and hence potentially exposing
patients to longer waiting times for surgery in order to coincide
with their allocated ‘phase’. In a review of menstrual timing of
breast cancer surgery by Hagen and Hrushesky (1998), the design
of this study was criticised. The timing of initial analysis was
criticised for being after only 2 years of follow-up; however, initial
analyses were planned when all patients had at least 3 years of
follow-up, and at the time of this analysis the median follow-up of
primary analysis patients was 59 months. The study was also
criticised for not using prospective menstrual history to comple-
ment retrospective menstrual history, for sampling hormone
concentrations infrequently, for multiple surgical procedures not
being coordinated in time, and for making no attempt to keep
clinicians, nurses and patients from biasing menstrual stage
assignment. However, this study has in fact collected dates of
menstrual bleeding prospectively, which have been used alongside
hormone profiles that have been well sampled at each intervention,
to define patients’ menstrual cycle phase. Due to UK waiting lists
and allocation of surgery timings it was not possible for us to look
at rapid succession of surgical interventions, and in this study the
median time between FTH and first surgery for primary analysis
patients was 17 days. Finally, as discussed above, no change in
practice was implemented for this study. All patients have been
followed up for 3 years, thus preventing differing follow-up for
patients in different menstrual cycle phases, and OS was chosen as
the primary endpoint as this will not be affected by clinicians
knowing at what stage surgery took place and therefore having
differing follow-up intensities between the menstrual cycle phases.
There has been no convincing biological hypothesis put forward
by those who have found a difference in survival. Many factors are
known to vary within the menstrual cycle, including oestrogen
receptor (ER) concentration (Pujol et al, 1998). The incidence of
vascular invasion has been shown to be higher in tumours
removed in the follicular phase (Fentiman, 2002), as have levels of
insulin like growth factor, interleukin-2, natural killer (NK)
activity and various gene changes (Souza et al, 2001). Two groups
have examined the prognostic impact of progesterone serum levels
based on the hypothesis that resection within the luteal phase gave
better outcome. Badwe et al (1994) showed no difference for node
negative patients, but a significant survival advantage was
observed for a small group in whom a high serum progesterone
level was reported at the time of resection.
Why were the early retrospective studies so positive? They came
from institutions with a good record of prospective collection of
data and where patients were dealt with in a very standardised
fashion. At Guy’s Hospital, the FTH was often an excision biopsy,
with definitive surgery carried out at a later stage. Details on
adjuvant therapy are scarce, but at the time of these studies many
patients did not receive chemotherapy or adjuvant tamoxifen. In
our study, 97.6% of patients received adjuvant therapy, with
approximately 70% receiving chemotherapy and/or tamoxifen and
80% of patients receiving radiotherapy. Modern chemotherapy
suppresses ovarian function, with cessation of menses in many
patients. This will depend on the type of regime used and the age
of the patient. It could therefore be hypothesised that predictive
factors such as menstrual cycle phase identified in these early
studies are now overruled by adjuvant therapy use.
At the time the ITS study was started it was not routine practice
to measure the ERa status of all breast cancers. It has since been
recognised that ERa status and markers of its functionality such as
progesterone receptor (PR) provide important prognostic infor-
mation, are predictive of response to anti-oestrogen therapy and
broadly delineate potentially different types of breast cancers
(Early Breast Cancer Trialists’ Collaborative Group, 1998). The
Surgical Timing And Menstrual Periods study was set up as a sub-
study to ITS in order to determine the ERa and PR status of
patients registered onto ITS. Longer-term survival subgroup
analysis will incorporate these data to assess whether differences
in survival according to the timing of interventions with respect to
menstrual cycle phase are apparent when accounting for ERa and
PR status.
To conclude, timing of breast cancer surgery in relation to the
menstrual cycle phase had no significant impact on 3-year survival
in this study. This may be due to almost all patients receiving some
form of adjuvant therapy. Longer-term analysis will be performed
at 10 years when all patients have reached this follow-up. This will
allow us to obtain a definitive answer to the controversial question
of the effect of timing of surgery with respect to patients’
menstrual cycle phase on prognosis.
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